## 2001 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 134 Hospitals

Hai-Rim Shin, M.D., Young-Joo Won, M.R.A., Kyu-Won Jung, M.S. and Jae-Gahb Park, M.D.

134 KCCR-affiliated Hospitals, Korea Central Cancer Registry, National Cancer Center, Goyang, Korea

<u>*Purpose:*</u> To estimate the number of cancer cases during 2001, in Korea, through a nationwide hospital based cancer registration by the Korea Central Cancer Registry (KCCR).

<u>Materials and Methods</u>: One hundred and thirty four hospitals participated in the KCCR program in 2001. Cancer cases were coded and classified according to the International Classification of Diseases for Oncology 2<sup>nd</sup> edition (ICD-O-2). The software program "IARC Check" was used to evaluate the quality of the registered cancer cases. Of the 111,816 malignancies registered, 10,106 (9.0%) duplicated malignancies were excluded. Among the remaining 95,542 malignancies, 3,598 (3.8%) cases with carcinoma in situ (Morphology code/2) were separated. Finally, 91,944 malignancies were analyzed.

<u>Results</u>: Of the total 91,944 malignancies, 51,753 (56.3%) cases were males and 40,191 (43.7%) were females.

### INTRODUCTION

The Korea Central Cancer Registry (KCCR) was started as an ambitious project of the Ministry of Health and Welfare in 1980 (1). In the beginning, 47 nationwide resident-training general hospitals participated in this program. The number of participating hospitals and registered malignancies increased year by year, and 134 hospitals submitted their data diskettes in 2001.

In 1996, the International Classification of Diseases for Oncology 2<sup>nd</sup> edition (ICD-O-2) was translated into Korean and distributed to all the participating hospitals. Topography and Morphology codes of the ICD-O-2 have been used since the 16<sup>th</sup> annual report of the KCCR.

The aim of this paper is to provide a summary of the 22<sup>nd</sup> annual report of the KCCR, which was published in February 2003 (1). It contains the relative frequencies of various cancers in the Republic of Korea, derived from the nationwide database of the hospital-based cancer registry program from January 1,

This study was supported by The National Cancer Center Grant 0110010.

More than one third of cases were from the elderly (65 years old and more). The six leading primary cancer sites, in the order of their relative frequency, were stomach (24.1%), followed by the lung (16.0%), the liver (16.0%), the colorectum (10.5%), the bladder (3.4%), and the prostate (2.8%) among males. In females, the breast (16.1%) was the common cancer site, followed by the stomach (15.3%), the colorectum (10.5%), the cervix uteri (10.1%), the thyroid gland (8.3%) and the lung (6.6%).

<u>Conclusion</u>: With the continued increase in cancer cases, the total number of registered cancer cases in Korea continues to rapidly increase. (Cancer Research and Treatment 2004;36:19-30)

Key Words: Cancer registry, Annual report

to December 31, 2001.

#### MATERIALS AND METHODS

One hundred and thirty four hospitals participated in the KCCR in 2001. All cancer registry data, submitted from the participating hospitals on diskettes during the year, were reviewed and sorted by qualified cancer registrars in the National cancer Center. After correction of erroneous coding of topography and morphology, cancer cases were classified according to the ICD-O-2. To avoid duplication, the computer compared the personal identification number of all subjects. The software program "IARC Check" which was freely distributed by International Association of Cancer Registry (IACR), was used to evaluate the quality of registered cancer cases. The pathologists working at the hospitals where the cases were diagnosed, reviewed the cases with errors shown from "IARC Check" program. Much emphasis was placed on the basis of diagnosis during this selection procedure. Cases diagnosed by histological examination were preferentially chosen.

Of 111,816 malignancies registered, 10,106 (9.0%) duplicated malignancies were excluded. Among the remaining 95,542 malignancies, 3,598 (3.8%) cases with carcinoma in situ (Morphology code/2) were separated. Finally, 91,944 malignancies were analyzed.

Correspondence: Jae-Gahb Park, National Cancer Center, Goyang-si, Gyeonggi-do 411-769, Korea. (Tel) 82-31-920-2050, (Fax) 82-31-920-2051, (E-mail) hrshin@ncc.re.kr

### RESULTS

# 1) Marginal frequency of malignant neoplasm and carcinoma in situ by age, sex, and topography

Of the total 91,944 registered malignancies 51,753 (56.3%) cases were males and 40,191 (43.7%) were females. The proportion of cancer cases among children (age  $0 \sim 14$ ) and among the elderly (65 and more) were 1.1 and 34.4%, respectively (Table 1).

The most common 10 primary sites among males were stomach (24.1%), lung (16.0%), liver (16.0%), colorectum (10.5%), blader (3.4%), prostate (2.8%), esophagus (2.7%), hematopoietic & reticuloendothelial systems (2.7%), pancreas (2.3%), and kidney (2.0%). Among females, they were the breast (16.1%), stomach (15.3%), colorectum (10.5%), cervix uteri (10.1%), thyroid (8.3%), lung (6.6%), liver (6.5%), ovary (3.8%), hematopoietic & reticuloendothelial systems (2.7%), and pancreas (2.1%) (Fig. 1).

The most common cancer among children  $(0 \sim 14 \text{ years old})$  was in the hematopoietic & reticuloendothelial systems, with 36.3% of boys and 34.1% of girls. For the age group  $15 \sim 34$ , stomach cancer was the most common cancer among males (17.9%) and thyroid cancer among females (22.5%). For the males in the older age groups, the stomach was leading site

 Table 1. Frequency of new cancer cases by gender and age in 2001, Korea

Age	]	Male	Fe	male	Т	Total		
group	N	%	Ν	%	N	%		
0	75	0.1	53	0.1	128	0.1		
$1\!\sim\!4$	237	0.5	172	0.4	409	0.4		
$5 \sim 9$	189	0.4	123	0.3	312	0.3		
$10\!\sim\!14$	160	0.3	127	0.3	287	0.3		
$15 \sim 19$	256	0.5	246	0.6	502	0.5		
$20\!\sim\!24$	298	0.6	468	1.2	766	0.8		
$25\!\sim\!29$	500	1.0	977	2.4	1,477	1.6		
$30\!\sim\!34$	869	1.7	1,778	4.4	2,647	2.9		
$35 \sim 39$	1,546	3.0	2,801	7.0	4,347	4.7		
$40\!\sim\!44$	2,825	5.5	4,151	10.3	6,976	7.6		
$45\!\sim\!49$	3,962	7.7	4,207	10.5	8,169	8.9		
$50\!\sim\!54$	5,233	10.1	3,954	9.8	9,187	10.0		
$55\!\sim\!59$	7,101	13.7	4,263	10.6	11,364	12.4		
$60\!\sim\!64$	9,071	17.5	4,696	11.7	13,767	15.0		
$65\!\sim\!69$	8,167	15.8	4,521	11.2	12,688	13.8		
$70\!\sim\!74$	5,774	11.2	3,663	9.1	9,437	10.3		
$75\!\sim\!79$	3,583	6.9	2,453	6.1	6,036	6.6		
$80\!\sim\!84$	1,438	2.8	1,044	2.6	2,482	2.7		
85+	469	0.9	494	1.2	963	1.0		
All	51,753	100.0	40,191	100.0	91,944	100.0		

of cancer, at 26.1% and 22.6% among  $35 \sim 64$  year olds and those 65 and over, respectively. However, among the females aged  $35 \sim 64$ , breast cancer was the most common cancer (22.1%), with stomach cancer being the most common among those 65 and over (20.1%) (Table 2).

Table 3 shows the number of carcinoma in situ cases by gender. 41.6% of registered uterine cervix cases were carcinomas in situ. However, only 6.8% of registered female breast cancer cases were diagnosed as carcinomas in situ.

# 2) Distribution of the six major cancers by topographic and morphologic type

Table 4 shows the primary sites and morphologic types of the six major cancers by gender.

More than one third of stomach cancer (C16) occurred in the antrum part of the stomach (34.1% in males and 32.7% in females, respectively), and half of these were adenocarcinomas (52.4% in males and 49.0% in females). For bronchus and lung cancers (C34), the major primary site was the upper lobe (31.6% in males and 26.3% in females), with squamous cell carcinomas (39.4%) the major morphologic type in males, but adenocarcinomas (40.0%) in females. In males, hepatocellular carcinomas accounted for 76.2% of the liver and intrahepatic bile ducts cancers (C22); however, in females this was 63.7%. For breast cancer, 35.6% of female breast cancer (C50) occurred in the upper outer part of the breast, with 82.6% being




Fig. 1. New cancer cases and proportion of cancer cases by major primary site and gender.

٨٩٩		Male		Female		
Age group	Rank –	Site	N (%)	Site	N (%)	
0~14	1	Hematopoietic	240 (36.3)	Hematopoietic	162 (34.1)	
	2	Brain	105 (15.9)	Brain	78 (16.4)	
	3	Adrenal gland	42 (6.4)	Adrenal gland	25 (5.3)	
	4	Bone and Joints and articular cartilage of limbs	30 (4.5)	Ovary	24 (5.1)	
	5	Testis	29 (4.4)	Bone and Joints and articular cartilage of limbs	21 (4.4)	
	6	Lymph nodes	29 (4.4)	Eye and adnexa	21 (4.4)	
	7	Connective, subcutaneous and other soft tissues	28 (4.2)	Thyroid gland	19 (4.0)	
	8	Eye and adnexa	27 (4.1)	Kidney	18 (3.8)	
	9	Kidney	24 (3.6)	Connective, subcutaneous and other soft tissues	16 (3.4)	
	10	Liver and intrahepatic bile ducts	16 (2.4)	Lymph nodes	16 (3.4)	
	etc		91 (13.8)		75 (15.8)	
	Subtotal		675		731	
15~34	1	Stomach	344 (17.9)	Thyroid gland	780 (22.5)	
	2	Hematopoietic	266 (13.8)	Breast	611 (17.6)	
	3	Liver and intrahepatic bile ducts	154 (8.0)	Stomach	375 (10.8)	
	4	Colorectum	132 (6.9)	Cervix uteri	342 (9.9)	
	5	Brain	130 (6.8)	Ovary	309 (8.9)	
	6	Lymph nodes	123 (6.4)	Hematopoietic	203 (5.9)	
	7	Thyroid gland	112 (5.8)	Colorectum	125 (3.6)	
	8	Testis	68 (3.5)	Brain	87 (2.5)	
	9	Bone and Joints and articular cartilage of limbs	63 (3.3)	Lymph nodes	66 (1.9)	
	10	Bronchus and lung	56 (2.9)	Corpus uteri	53 (1.5)	
	etc		475 (24.7)		518 (14.9)	
	Subtotal		1,836		3,521	
35~64	1	Stomach	7,747 (26.1)	Breast	5,311 (22.1	
	2	Liver and intrahepatic bile ducts	6,073 (20.4)	Stomach	3,346 (13.9)	
	3	Bronchus and lung	3,839 (12.9)	Cervix uteri	2,987 (12.4	
	4	Colorectum	3,265 (11.0)	Colorectum	2,188 (9.1)	
	5	Bladder	844 (2.8)	Thyroid gland	2,161 (9.0)	
	6	Esophagus	762 (2.6)	Liver and intrahepatic bile ducts	1,450 (6.0)	
	7	Kidney	697 (2.3)	Bronchus and lung	1,214 (5.0)	
	8	Pancreas	656 (2.2)	Ovary	939 (3.9)	
	9	Hematopoietic	622 (2.1)	Corpus uteri	565 (2.4)	
	10	Larynx	538 (1.8)	Hematopoietic	461 (1.9)	
	etc		4,695 (15.8)		3,450 (14.3	
	Subtotal		30,752		25,994	

Table 2. Frequency of major cancer cases by gender and age in 2001, Korea

Age		Male		Female			
group	Rank	Site	N (%)	Site	N (%)		
65+	1	Stomach	4,388 (22.6)	Stomach	2,442 (20.1)		
	2	Bronchus and lung	4,385 (22.6)	Colorectum	1,903 (15.6)		
	3	Colorectum	2,074 (10.7)	Bronchus and lung	1,372 (11.3)		
	4	Liver and intrahepatic bile ducts	2,018 (10.4)	Liver and intrahepatic bile ducts	1,095 (9.0)		
	5	Prostate gland	1,079 (5.6)	Cervix uteri	731 (6.0)		
	6	Bladder	857 (4.4)	Breast	547 (4.5)		
	7	Esophagus	657 (3.4)	Pancreas	510 (4.2)		
	8	Pancreas	517 (2.7)	Thyroid gland	357 (2.9)		
	9	Other and unspecified parts of biliary tract	436 (2.2)	Gallbladder	339 (2.8)		
	10	Larynx	382 (2.0)	Other and unspecified parts of biliary tract	323 (2.7)		
	etc		2,638 (13.6)		2,556 (21.0)		
	Subtotal		22,135		13,599		

Table 2. Continued

Table 3. Frequency of primary in-situ cases in 2001, Korea

Rank	Male				Female			
		Malignant	in-situ (n=122)		Malignant	in-situ (n=3,476		
	N (%)	N (%)	Primary site	N (%)	N (%)			
1	Skin	648 (96.9)	33 (1.8)	Cervix	4,061 (58.4)	2,898 (41.6)		
2	Bladder	1,734 (99.2)	29 (3.1)	Breast	6,469 (93.2)	473 (6.8)		
3	Colon	2,657 (99.5)	25 (3.7)	Skin	613 (95.8)	27 (4.2)		
4	Stomach	12,481 (99.9)	24 (0.8)	Colon	2,139 (99.4)	12 (0.6)		
5	Larynx	923 (98.9)	20 (0.2)	Vagina	49 (80.3)	12 (19.7)		
etc.		33,310 (99.9)	64 (0.2)	-	26,860 (99.8)	54 (0.2)		

infiltrating duct carcinomas. The most common site of colon cancer (C18) was the sigmoid colon (39.8% in males and 35.7% in females, respectively) and the most frequent morphologic type was adenocarcinomas (60.0% in males and 60.1% in females). Only 11.2% of male and 11.1% of female rectal cancers occurred in the rectosigmoid junction. As with other cancers, adenocarcinomas were the major morphologic type of rectal cancer (62.5% in males and 60.6% in females).

Appendix 2 shows the distribution of cancer cases by ICD-10 for easy comparison of the cancer death statistics.

#### DISCUSSION

Information on the incidence and mortality of cancers, and their changing trends, is an essential component in the planning and monitoring of programs for cancer prevention, early detection and treatment (2).

The Korea Central Cancer Registry (KCCR) was started as an ambitious project of the Ministry of Health and Welfare

Male				Female					
Topography	Cases (%)	Morphology	Cases (%)	Topography	Cases (%)	Morphology	Cases (%		
Stomach (C16)									
Gastric antrum	4,258	Adenocarcinoma	6,539	Gastric antrum	2,015	Adenocarcinoma	3,020		
	(34.1)		(52.4)		(32.7)		(49.0)		
Body	2,900	Tubular adeno ca.	3,041	Body	1,623	Signet ring cell ca.	1,315		
	(23.2)		(24.4)		(26.3)		(21.3)		
Overlapping	1,698	Signet ring cell ca.	1,599	Overlapping	838	Tubular adeno ca.	1,079		
lesion	(13.6)		(12.8)	lesion	(13.6)		(17.5)		
Cardia, NOS	483	Mucinous adeno ca.	187	Cardia, NOS	170	Mucinous adeno ca.	98		
	(3.9)		(1.5)		(2.8)		(1.6)		
Lesser curvature	394	Papillary adeno ca.	95	Lesser curvature	164	Leiomyosarcoma	73		
	(3.2)		(0.8)		(2.7)		(1.2)		
	2,748		1,020		1,357		582		
	(22.0)		(8.2)		(22.0)		(9.4)		
Bronchus and lung	g (C34)								
Upper lobe	2,617	Squamous cell ca.	3,266	Upper lobe	693	Adenocarcinoma	1,056		
	(31.6)		(39.4)		(26.3)		(40.0)		
Lower lobe	1,773	Adenocarcinoma	1,838	Lower lobe	592	Squamous cell ca.	349		
	(21.4)		(22.2)		(22.4)		(13.2)		
Main bronchus	375	Small cell ca.	1,201	Middle lobe	137	Small cell ca.	245		
	(4.5)		(14.5)		(5.2)		(9.3)		
Middle lobe	312	Bronchiolo-alveolar.	68	Main bronchus	73	Bronchiolo-alveolar	104		
	(3.8)	adeno ca.	(0.8)		(2.8)	adeno ca.	(3.9)		
Overlapping lesion		Carcinoid tumor	59	Overlapping lesion		Acinar cell ca.	41		
	(2.9)		(0.7)		(2.7)		(1.6)		
Lung, NOS	2,966		1,852	Lung, NOS	1,072		843		
	(35.8)		(22.4)		(40.6)		(32.0)		
Liver and intrahep	oatic bile du	ucts (C22)							
Liver	7,062	Hepatocellular ca.	6,293	Liver	1,905	Hepatocellular ca.	1,654		
	(85.5)		(76.2)		(73.4)		(63.7)		
Intrahepatic	1,199	Cholangiocarcinoma	418	Intrahepatic	690	Cholangiocarcinoma	213		
bile duct	(14.5)		(5.1)	bile duct	(26.6)		(8.2)		
		Adenocarcinoma	173			Adenocarcinoma	92		
			(2.1)				(3.5)		
		Combined hepatocellula				Hepatoblastoma	10		
		ca and cholangio ca.	(0.3)				(0.4)		
		Tubular adeno ca./	10			Combined hepatocellula			
		Hepatoblastoma	(0.1)			ca and cholangio ca./ Tubular adeno ca.	(0.3)		
			1,330				610		
			(16.1)				(23.5)		

Table 4. Frequency of topography and morphology in major cancer sites

Male				Female				
Topography	Cases (%)	Morphology	Cases (%)	Topography	Cases (%)	Morphology	Cases (%	
Breast (C50)								
				Upper outer	2,300	Infiltrating duct ca.	5,346	
					(35.6)		(82.6)	
				Overlapping	839	Lobular ca.	221	
				lesion	(13.0)		(3.4)	
				Upper inner	752	Mucinous adeno ca.	144	
					(11.6)		(2.2)	
				Lower outer	371	Medullary ca.	116	
					(5.7)		(1.8)	
				Central portion	329	Papillary ca.	80	
				-	(5.1)		(1.2)	
					1,878		562	
					(29.0)		(8.7)	
Rectum (C19-C20								
	·							
Rectum, NOS	2,501	Adenocarcinoma	1,762	Rectum, NOS	1,850	Adenocarcinoma	1,261	
	(88.8)		(62.5)		(88.9)		(60.6)	
Rectosigmoid	316	Tubular adeno ca.	677	Rectosigmoid	232	Tubular adeno ca.	478	
junction	(11.2)		(24.0)	junction	(11.1)		(23.0)	
		Mucinous adeno ca	a. 73			Mucinous adeno ca.	66	
			(2.6)				(3.2)	
		Carcinoid tumor	48			Papillary adeno ca.	48	
			(1.7)				(2.3)	
		Papillary adeno ca.	48			Carcinoid tumor	28	
			(1.7)				(1.3)	
			209				201	
			(7.4)				(9.7)	
Colon (C18)								
Sigmoid colon	1,057 (60.0)	Adenocarcinoma	1,593 (35.7)	Sigmoid colon	763 (39.8)	Adenocarcinoma	1,286 (60.1)	
Ascending colon	494	Tubular adeno ca.	559	Ascending color		Tubular adeno ca.	431	
8	(18.6)		(21.0)	U	(24.2)		(20.1)	
Fransverse colon	206	Mucinous adeno ca		Transverse color		Mucinous adeno ca.	149	
	(7.8)		(6.1)		(7.6)		(7.0)	
Descending colon		Papillary adeno ca.		Cecum	136	Papillary adeno ca.	40	
cooling colon	(5.7)	rupinurj udeno ed.	(2.5)	cooum	(6.4)	2 upinui j udeno ed.	(1.9)	
Cecum	126	Malig. Lymphoma,		Descending colo		Malig. Lymphoma,	1.5)	
		large cell, diffuse		Destending Cold		large cell, diffuse		
	(4.7)	large cell, diffuse			(4.7)	large cell, diffuse	(0.7)	
	622		249		460		218	
	(23.4)		(9.4)		(21.5)		(10.2)	

#### Table 4. Continued

in 1980. In the beginning, 47 nationwide resident-training general hospitals participated in this program. The number of participating hospitals and registered malignancies has increased year-by-year, with 134 hospitals submitting their data diskettes in 2001 (1). The number of cancer cases in the KCCR for 2000 was assumed to be more than 90% precise for cancer cases, with the comparison of the estimated cancer incidence cases (3), using national mortality data, and the incidence data from four frontier regional cancer registries, including Kangwha, Seoul, Busan and Daegu, in the Cancer Incidence in Five Continents (4).

The KCCR database is especially useful for showing the trend of cancer occurrence in Korea, as information on the changing trend of cancer incidence over time is an essential component in the planning and monitoring of programs for cancer prevention, early detection and treatment. Major cancers, including stomach, lung, liver, breast and colorectum, but with the exception of uterine cervix cancer, were increasing (data not shown). For uterine cervix cancer, the proportion of carcinoma in-situ cases increased among the registered cases, meaning significant uterine cervix cancers were detected at an early stage.

Currently, KCCR, being a nationwide hospital-based cancer registry, is supporting technically and financially 9 populationbased regional registries; Seoul, Busan, Daegu, Incheon, Gwangju, Daejeon, Ulsan, Jejudo and Goyang-si in 2003.

The KCCR database continues to hold the most important position until a nationwide, population-based data acquisition program can be constructed on the basis of international standards.

One area for caution in the interpretation of the KCCR data

is that the numbers outlined in this report do not represent persons, but cases that have been reported. The patients who had cancers at several sites have been treated as multiple primary patients, and have been reported according to the cancer site.

#### ACKNOWLEDGEMENTS

We would like to sincerely thank the participation of the medical record administrators in the KCCR-affiliated hospitals [Appendix 1] who enthusiastically participated in the KCCR by registering new cancer cases. We would also like to thank Ji-Young Kim, M.R.A., Su-Jin Kim, M.S., Hye-Jin Kim, M.R.A., Kwang-Suk Park, M.R.A., and Ji-Young Oh, M.R.A. for their devoted efforts to mining and clearing the KCCR data set.


#### REFERENCES

- 1. Ministry Health and Welfare. 2001 Annual report of Korea Central Cancer Registry (published in 2003). Available from URL:http://www.ncc.re.kr
- 2. WHO IARC. Cancer Registration; Principles and methods, 1991. Lyon, France
- Shin HR, Ahn YO, Bae JM, Shin MH, Lee DH, Lee CW, Ohrr HC, Ahn DH, Ferlay J, Parkin DM, Oh DK, Park JG. Cancer Incidence in Korea. Cancer Research and Treatment 2002; 405-408
- 4. WHO IARC, Cancer Incidence in Five Continents. Volume VIII, 2002

	Appendix 1	. List	of the	Hospitals	participating	in the	2001	KCCR	program
--	------------	--------	--------	-----------	---------------	--------	------	------	---------

Ajou University Hospital Andong General Hospital Andong Presbyterian Hospital Ansan Hando General Hospital Asan Medical Center Bag Ae Hospital Benedict Hospital Bupyeong Serim Hospital Busan Veterans Hospital Carollo Hospital Catholic GEN Hospital Changwon Fatima Hospital Changwon General Hospital ChonBuk National University Hospital Chongju St. Mary's Hospital Chonnam University Hospital Choon Hae Hospital Chosun University Hospital Chung-Ang University Hospital ChungAng University Medical Center Chungbuk National University Hospital Chungnam National University Hospital College of Medicine, Pochon CHA university CHA General Hospital Dae Dong hospital Dae Jeon Veterans Hospital Dae Rim St. Mary's Hospital Daegu Medical Center Daewoo Hospital DanKook University Hospital Dong Kang General Hospital Dong Rae Bong Seng Hospital Dong-A University Hospital Dongeui Medical Center Dongguk University Kyong Ju Hospital Dong-In Hospital Dong-Kuk University Po-Hang Hospital Dongsan Medical Center Ewha Womans University Mokdong Hospital Ewha Womans University Tongdaemun Hospital Gachon Medical School Gil Medical Center Gangneung Asan Hospital Gangneung Medical Center Gyeongsang University Hospital Hae Dong Hospital Halla General hospital Hallym Sacred Heart Hospital

Appendix 1. Continued



Presbyterian Medical Center Pundang Je-Saeng Hospital Pusan Adventist Hospital Pusan Medical Center Pusan National University Hospital Samsun Hospital Samsung Medical center Sansung Cheil Hospital & Women's Health Care Center Sejong General Hospital Seo San Medical Center Seoul Adventist Hospital Seoul Municipal Boramae Hospital Seoul National University Hospital Seoul Red Cross Hospital Severance Hospital Yonsei University Medical College Shin Chun Hospital Soonchunhyang GuMi Hospital Soonchunhyang University Cheonan Hospital Soonchunyang Univ. Hospital St, Mary's hospital, The Catholic University of Korea St. Francisco General Hospital St. Paul's Hospital Sun General Hospital Sung Ae Hospital Taeback Choongang General Hospital Taegu Catholic University Hospital Taegu Fatima Hospital The Catholic University of Korea Kangnam St. Mary's Hospital The Catholic University of Korea Taejon St. Mary's Hospital The Catholic University of Korea, Our Lady of mercy Hospital The Catholic University of Korea, St. Vincent's Hospital Uijongbu St. Mary's Hospital The Catholic University of Korea Ulsan University Hospital Wallace Memorial Baptist Hospital WonJu Christian Hospital, Won Ju Clooege of Medicine, Yonsei University WonKwang University Hospital Yeungnam University Medical Center Yeungnam University Youngchun Hospital Yonsei Medical center, Yong-Dong Severance Hospital Young Dong Hospital

Ap	pendix	1.	Continued
----	--------	----	-----------

Site (code)	Mal	e	Fe	emale
She (code)	n	%	n	%
Lip (C00)	17	0.0	11	0.0
Tongue (C01~02)	209	0.4	79	0.2
Mouth (C03~06)	242	0.5	99	0.2
Salivary glands (C07 $\sim$ 08)	136	0.3	107	0.3
Tonsil (C09)	109	0.2	15	0.0
Other oropharynx (C10)	46	0.1	6	0.0
Nasopharynx (C11)	218	0.4	81	0.2
Hypopharynx (C12~13)	239	0.5	14	0.
Pharynx unspecified (C14)	27	0.1	3	0.
Oesophagus (C15)	1416	2.7	120	0.
Stomach (C16)	12,356	23.9	6,050	15.
Small intestine (C17)	204	0.4	140	0.
Colon (C18)	2,620	5.1	2,112	5.
Rectum (C19~20)	2,814	5.4	2,073	5.
Anus (C21)	59	0.1	62	0.2
Liver (C22)	8259	16.0	2,596	6.
Gallbladder etc.(C23~24)	1361	2.6	1,241	3.
Pancreas (C25)	1187	2.3	854	2.
Nose, sinuses etc.(C30 $\sim$ 31)	148	0.3	81	0.1
Larynx (C32)	920	1.8	71	0.1
TrecheaTrachea, bronchus and lung (C33 $\sim$ 34)	8,292	16.0	2,632	6.
Other thoracic organs $(C37 \sim 38)$	157	0.3	89	0.1
Bone (C40 $\sim$ 41)	218	0.4	191	0.:
Melanoma of skin (C43)	112	0.2	111	0.
Other skin (C44)	509	1.0	493	1.1
Mesothelioma (C45)	27	0.1	11	0.0
Kaposi sarcoma (C46)	7	0.0	6	0.0
Connective and soft tissue (C47 $\sim$ 49)	294	0.6	251	0. 0.
Breast (C50)	36	0.1	6,459	16.
Vulva (C51)	50	0.1	67	0.2
Vagina (C52)	-	-	48	0.2
Cervix uteri (C53)	-	-	4,054	10.1
Corpus uteri (C54)	-	-	739	1.8
Uterus unspecified (C55)	-	-		
• · · ·	-	-	61	0.2
Ovary (C56) Other female genital organs (C57)	-	-	1,520 34	3.8 0.1
	-	-		
Placenta (C58)	0	0.0	69	0.2
Penis (C60)	44	0.1	-	-
Prostate (C61)	1,466	2.8	-	-
Testis (C62)	133	0.3	-	-
Other male genital organs (C63)	28	0.1	-	-
Kidney (C64)	1,011	2.0	465	1.
Renal pelvis (C65)	128	0.2	29	0.
Ureter (C66)	117	0.2	62	0.
Bladder (C67)	1730	3.3	415	1.

Appendix 2. Marginal frequency of malignant cases by sexgender and ICD-10 grouping in 2001

	Ma		Female		
Site (code)	n	%	n	%	
Other urinary organs (C68)	21	0.0	24	0.1	
Eye (C69)	51	0.1	40	0.1	
Brain, nervous system (C70~72)	609	1.2	489	1.2	
Thyroid (C73)	551	1.1	3,305	8.2	
Adrenal gland (C74)	71	0.1	48	0.1	
Other endocrine (C75)	46	0.1	20	0.0	
Hodgkin disease (C81)	92	0.2	42	0.1	
Non-Hodgkin lymphoma (C82~85, C96)	1,185	2.3	793	2.0	
Immunoproliferative diseases (C88)	9	0.0	0	0.0	
Multiple myeloma (C90)	267	0.5	202	0.5	
Lymphoid leukaemia (C91)	290	0.6	194	0.5	
Myeloid leukaemia (C92~94)	645	1.2	555	1.4	
Leukaemia unspecified (C95)	39	0.1	39	0.1	
Other and unspecified (C26, C39, C48, C76, C80, C97)	981	1.9	819	2.0	

Appendix 2. Continued